Company Profile

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit

Industry Classifications






Research and Development in the Physical, Engineering, and Life Sciences (541710)


Commercial Physical and Biological Research (8731)

Contact Information

Investor Relations

Sutro Biopharma
Emily White
Investor Relations and Communications Advisor
T: 650-823-7681

Company Contact

Sutro Biopharma, Inc.
111 Oyster Point Blvd
South San Francisco, CA 94080